UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 151

Sortiert nach

Significance of Tumor Microenvironment for Regulating Pancreatic Cancer

Cancers, 2023-04, Vol.15 (9), p.2482

Ijichi, Hideaki

2023

Link zum Volltext

Verfügbarkeit prüfen

Targeting mutated KRAS in the first‐line therapy

Clinical and translational discovery, 2024-04, Vol.4 (2), p.n/a

Ijichi, Hideaki

2024

Link zum Volltext

Verfügbarkeit prüfen

The Role of the Microbiome in Pancreatic Cancer

Cancers, 2022-09, Vol.14 (18), p.4479

2022

Link zum Volltext

Verfügbarkeit prüfen

Loss of 5‐hydroxymethylcytosine is accompanied with malignant cellular transformation

Cancer science, 2012-04, Vol.103 (4), p.670-676

2012

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of CXCLs/CXCR2 axis in the tumor microenvironment might be a potent therapeutics for pancreatic cancer

Oncoimmunology, 2012-07, Vol.1 (4), p.569-571

Ijichi, Hideaki

2012

Link zum Volltext

Verfügbarkeit prüfen

Mirogabalin improves cancer-associated pain but increases the risk of malignancy in mice with pancreatic cancer

Pain (Amsterdam), 2023-07, Vol.164 (7), p.1545-1554

2023

Link zum Volltext

Verfügbarkeit prüfen

Indirubin 3′-Oxime Inhibits Migration, Invasion, and Metastasis In Vivo in Mice Bearing Spontaneously Occurring Pancreatic Cancer via Blocking the RAF/ERK, AKT, and SAPK/JNK Pathways

Translational oncology, 2019-12, Vol.12 (12), p.1574-1582

2019

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of transforming growth factor-β signaling in myeloid cells ameliorates aortic aneurysmal formation in Marfan syndrome

PloS one, 2020-11, Vol.15 (11), p.e0239908-e0239908

2020

Link zum Volltext

Verfügbarkeit prüfen

A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel

Investigational new drugs, 2021-04, Vol.39 (2), p.605-613

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis

The New England journal of medicine, 2024-05, Vol.390 (20), p.1934

Ijichi, Hideaki

2024

Link zum Volltext

Verfügbarkeit prüfen

Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47Δ and immune checkpoint inhibitors

Molecular therapy. Oncolytics, 2023-03, Vol.28, p.31-43

2023

Link zum Volltext

Verfügbarkeit prüfen

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

The New England journal of medicine, 2015-11, Vol.373 (20), p.1979-1979

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1

Cancer science, 2012-08, Vol.103 (8), p.1489-1492

2012

Link zum Volltext

Verfügbarkeit prüfen

Identification of a Suppressive Mechanism for Hedgehog Signaling through a Novel Interaction of Gli with 14-3-3

The Journal of biological chemistry, 2010-02, Vol.285 (6), p.4185-4194

2010

Link zum Volltext

Verfügbarkeit prüfen

Impact of S-1 in Patients with Gemcitabine-refractory Pancreatic Cancer in Japan

Japanese journal of clinical oncology, 2010-08, Vol.40 (8), p.774-780

2010

Link zum Volltext

Verfügbarkeit prüfen

Smad4 is Essential for Down-regulation of E-cadherin Induced by TGF-β in Pancreatic Cancer Cell Line PANC-1

Journal of biochemistry (Tokyo), 2007-03, Vol.141 (3), p.345-351

2007

Link zum Volltext

Verfügbarkeit prüfen

Genetically-engineered mouse models for pancreatic cancer: Advances and current limitations

World journal of clinical oncology, 2011-05, Vol.2 (5), p.195-202

Ijichi, Hideaki

2011

Link zum Volltext

Verfügbarkeit prüfen

Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis

The New England journal of medicine, 2024-05, Vol.390 (20), p.1933-1936

2024

Link zum Volltext

Verfügbarkeit prüfen

Analysis of the β‐Catenin/T Cell Factor Signaling Pathway in 36 Gastrointestinal and Liver Cancer Cells

Cancer science, 2002-11, Vol.93 (11), p.1213-1220

2002

Link zum Volltext

Verfügbarkeit prüfen

Protein intake after the initiation of chemotherapy is an independent prognostic factor for overall survival in patients with unresectable pancreatic cancer: A prospective cohort study

Clinical nutrition (Edinburgh, Scotland), 2021-07, Vol.40 (7), p.4792-4798

2021

Link zum Volltext

Verfügbarkeit prüfen

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

The New England journal of medicine, 2015-11, Vol.373 (20), p.1979

2015

Link zum Volltext

Verfügbarkeit prüfen

Abstract C47: Plasma ANP and soluble cell adhesion molecule X are novel risk factors for pancreatic cancer-associated thrombosis

Cancer research (Chicago, Ill.), 2019-12, Vol.79 (24_Supplement), p.C47-C47

2019

Link zum Volltext

Verfügbarkeit prüfen

The Effect of Renin-Angiotensin System Inhibitors in Patients Undergoing Pancreatic Cancer Resection

Pancreas, 2024-03, Vol.53 (3), p.e233

2024

Link zum Volltext

Verfügbarkeit prüfen

Effects of tramadol via a µ-opioid receptor on pancreatic ductal adenocarcinoma in vitro and in vivo

Regional anesthesia and pain medicine, 2023-06, Vol.49 (3), p.200

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 151

Suche als RSS-Feed

Aktive Filter

SpracheJapanisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(141)
Mit Volltextzugriff
(143)

Publikationsform

Artikel
(149)
Berichte
(2)

Sprache

Englisch
(151)

Erscheinungsjahr

n.n

Thema

Science & Technology
(71)
Life Sciences & Biomedicine
(70)
Humans
(58)
Male
(35)
Female
(34)
Pancreatic Cancer
(32)
Middle Aged
(29)
Oncology
(29)
Aged
(25)
Tumors
(23)
Gastroenterology And Hepatology
(22)
Gastroenterology & Hepatology
(21)
Animals
(19)
Biological And Medical Sciences
(19)
Medical Sciences
(19)
Pancreatic Neoplasms - Drug Therapy
(17)
Chemotherapy
(16)
Adult
(15)
Mice
(15)
Aged, 80 And Over
(14)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Significance of Tumor Microenvironment for Regulating Pancreatic Cancer

Targeting mutated KRAS in the first‐line therapy

The Role of the Microbiome in Pancreatic Cancer

Loss of 5‐hydroxymethylcytosine is accompanied with malignant cellular transformation

Inhibition of CXCLs/CXCR2 axis in the tumor microenvironment might be a potent therapeutics for pancreatic cancer

Mirogabalin improves cancer-associated pain but increases the risk of malignancy in mice with pancreatic cancer

Indirubin 3′-Oxime Inhibits Migration, Invasion, and Metastasis In Vivo in Mice Bearing Spontaneously Occurring Pancreatic Cancer via Blocking the RAF/ERK, AKT, and SAPK/JNK Pathways

Inhibition of transforming growth factor-β signaling in myeloid cells ameliorates aortic aneurysmal formation in Marfan syndrome

A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel

Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis

Overcoming resistance of stroma-rich pancreatic cancer with focal adhesion kinase inhibitor combined with G47Δ and immune checkpoint inhibitors

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1

Identification of a Suppressive Mechanism for Hedgehog Signaling through a Novel Interaction of Gli with 14-3-3

Impact of S-1 in Patients with Gemcitabine-refractory Pancreatic Cancer in Japan

Smad4 is Essential for Down-regulation of E-cadherin Induced by TGF-β in Pancreatic Cancer Cell Line PANC-1

Genetically-engineered mouse models for pancreatic cancer: Advances and current limitations

Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis

Analysis of the β‐Catenin/T Cell Factor Signaling Pathway in 36 Gastrointestinal and Liver Cancer Cells

Protein intake after the initiation of chemotherapy is an independent prognostic factor for overall survival in patients with unresectable pancreatic cancer: A prospective cohort study

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Abstract C47: Plasma ANP and soluble cell adhesion molecule X are novel risk factors for pancreatic cancer-associated thrombosis

The Effect of Renin-Angiotensin System Inhibitors in Patients Undergoing Pancreatic Cancer Resection

Blocking VCAM-1 inhibits pancreatic tumour progression and cancer-associated thrombosis/thromboembolism

Effects of tramadol via a µ-opioid receptor on pancreatic ductal adenocarcinoma in vitro and in vivo

Aktive Filter

Suchergebnisse filtern